Synaptogenix (SNPX) Competitors $8.50 +0.42 (+5.20%) As of 07/3/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNPX vs. MIRA, BCTX, JATT, DRRX, CARM, BIVI, QTTB, AYTU, ERNA, and MTEXShould you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include MIRA Pharmaceuticals (MIRA), Briacell Therap (BCTX), JATT Acquisition (JATT), DURECT (DRRX), Carisma Therapeutics (CARM), BioVie (BIVI), Q32 Bio (QTTB), Aytu BioPharma (AYTU), Ernexa Therapeutics (ERNA), and Mannatech (MTEX). These companies are all part of the "pharmaceutical products" industry. Synaptogenix vs. Its Competitors MIRA Pharmaceuticals Briacell Therap JATT Acquisition DURECT Carisma Therapeutics BioVie Q32 Bio Aytu BioPharma Ernexa Therapeutics Mannatech MIRA Pharmaceuticals (NASDAQ:MIRA) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment. Which has more volatility and risk, MIRA or SNPX? MIRA Pharmaceuticals has a beta of 1.72, suggesting that its stock price is 72% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Does the media prefer MIRA or SNPX? In the previous week, MIRA Pharmaceuticals had 2 more articles in the media than Synaptogenix. MarketBeat recorded 3 mentions for MIRA Pharmaceuticals and 1 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.00 beat MIRA Pharmaceuticals' score of -0.33 indicating that Synaptogenix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MIRA Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Synaptogenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger valuation & earnings, MIRA or SNPX? MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMIRA PharmaceuticalsN/AN/A-$7.85M-$0.51-2.30SynaptogenixN/AN/A-$12.77M-$10.08-0.84 Is MIRA or SNPX more profitable? Synaptogenix's return on equity of -115.28% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MIRA PharmaceuticalsN/A -341.08% -272.93% Synaptogenix N/A -115.28%-58.31% Do analysts prefer MIRA or SNPX? MIRA Pharmaceuticals currently has a consensus target price of $14.00, suggesting a potential upside of 1,091.49%. Synaptogenix has a consensus target price of $14.00, suggesting a potential upside of 64.71%. Given MIRA Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe MIRA Pharmaceuticals is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals hold more shares of MIRA or SNPX? 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Comparatively, 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryMIRA Pharmaceuticals beats Synaptogenix on 10 of the 14 factors compared between the two stocks. Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNPX vs. The Competition Export to ExcelMetricSynaptogenixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.82M$2.88B$5.50B$9.01BDividend YieldN/A2.43%5.38%4.04%P/E Ratio-0.8421.5627.6020.30Price / SalesN/A172.94369.09103.84Price / CashN/A41.9536.6357.47Price / Book1.967.518.055.68Net Income-$12.77M-$55.05M$3.18B$249.13M7 Day Performance40.50%4.61%2.82%3.30%1 Month Performance225.67%4.89%3.70%5.20%1 Year Performance109.36%5.84%35.41%21.38% Synaptogenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNPXSynaptogenix1.214 of 5 stars$8.50+5.2%$14.00+64.7%+99.0%$11.82MN/A-0.844Gap DownMIRAMIRA Pharmaceuticals2.8182 of 5 stars$1.29+11.2%$14.00+985.3%+104.3%$19.71MN/A-2.532BCTXBriacell Therap2.5627 of 5 stars$2.97+3.1%$32.00+977.4%-80.6%$19.51MN/A-0.368High Trading VolumeJATTJATT AcquisitionN/A$1.12-0.9%N/A-67.3%$19.32MN/A0.003High Trading VolumeDRRXDURECT0.5687 of 5 stars$0.64+4.0%N/A-47.9%$19.25M$2.03M-4.3080Gap DownCARMCarisma Therapeutics1.9055 of 5 stars$0.43-5.2%$1.93+350.2%-70.8%$18.84M$19.63M-0.2720Gap DownBIVIBioVie0.67 of 5 stars$1.07+5.9%$3.00+180.4%+131.4%$18.76MN/A-0.1410Gap DownQTTBQ32 Bio2.2466 of 5 stars$1.59+3.9%$12.17+665.2%-91.7%$18.66M$1.16M-0.3239AYTUAytu BioPharma3.7227 of 5 stars$2.04+3.0%N/A-13.7%$17.77M$81M-2.83160Analyst ForecastERNAErnexa Therapeutics0.6768 of 5 stars$1.98-17.5%N/A-92.7%$17.68M$580K-0.2410Negative NewsHigh Trading VolumeMTEXMannatech0.2962 of 5 stars$9.20+0.1%N/A+37.8%$17.47M$117.87M-92.00250 Related Companies and Tools Related Companies MIRA Pharmaceuticals Alternatives Briacell Therap Alternatives JATT Acquisition Alternatives DURECT Alternatives Carisma Therapeutics Alternatives BioVie Alternatives Q32 Bio Alternatives Aytu BioPharma Alternatives Ernexa Therapeutics Alternatives Mannatech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNPX) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synaptogenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SNPX Stock Alerts